Peptides

Peptide
#AltPep Corporation #Alzheimer's #Neurodegenerative disorders #Peptides

Custom-designed peptide could treat Alzheimer’s 

New findings show a custom-designed peptide has promising potential as a treatment for early Alzheimer’s disease (AD).  The candidate SOBIN-AD, developed by biotechnology company AltPep Corporation, demonstrated potential to improve cognition both before and after the onset of cognitive impairment in pre-clinical trial. SOBIN-AD also reduced Aβ… Read More

#News

Neurons
#Dementia #Neurodegenerative disorders #Parkinson's #Peptides #University of Bath

Scientists design peptide ‘switch’ to slow Parkinson’s progress

Researchers at the University of Bath, in collaboration with the Universities of Oxford and Bristol, have developed a molecule that prevents the clumping and build-up of alpha-synuclein, a protein linked to Parkinson’s disease and related dementias.   The team has successfully demonstrated it works in an animal model… Read More

#News #Trending News

#Artificial intelligence (AI) #Collaboration #Drug discovery #Peptides

AI-powered platform could accelerate peptide drug discovery

CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery.  The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK.  The combined platform aims… Read More

#News

#AltPep Corporation #Alzheimer's #Neuroscience #Peptides

Peptide for Alzheimer’s increases clearance of amyloid plaques

AltPep Corporation has presented new preclinical data on its lead compound, Soluble Oligomer Binding Inhibitor (SOBIN-AD), as a treatment for early Alzheimer’s disease (AD) at the Alzheimer’s Association International Conference (AAIC).   The preclinical data show SOBIN-AD:  Binds amyloid beta (Aβ) oligomers 27,000-fold stronger than… Read More

#News

#Oncology #Peptides #Transcriptomics #University of Bath

Promising drug candidates for previously ‘undruggable’ target

Reportedly for the first time, researchers from the University of Bath have identified  promising  drug candidates that bind irreversibly with a notoriously ‘undruggable’ cancer protein target, permanently blocking it. Transcription factors are proteins that act as ‘master switches’ of gene activity and play a key role in cancer… Read More

#Cancer Research #News #Trending News

Two scientists working in a research laboratory
#Cancer Research UK #Oncology #Peptides #Phase II trial #Rare cancers

UK-Norwegian collaboration to trial peptide for rare cancer

Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC).  CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer… Read More

#Business & Investment #Cancer Research #News

Stomach pain
#Chronic pain #Irritable Bowel Syndrome #Painkillers #Peptides #University of Queensland

Highly promising new oral approach to abdominal pain

University of Queensland (UQ) researchers have developed a new class of oral painkillers to suppress chronic abdominal pain that is based on the peptide hormone oxytocin. The team changed the chemical structure of oxytocin to make it gut-stable after earlier work revealed the hormone could treat… Read More

#News #Trending News

Central nervous system
#Biotechnology #Nervgen #Nervous system disorders #Peptides #Spinal cord injury

Empowering the nervous system to repair itself

NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and… Read More

#Exclusive Content #Opinion

Peptide
#Cybrexa Therapeutics #Oncology #Ovarian cancer #Peptide-drug conjugate #Peptides #Phase II trial

Peptide-drug conjugate demonstrates antitumour activity

Cybrexa Therapeutics has dosed the first patient in a Phase II trial of its peptide-drug conjugate (PDC) CBX-12 in ovarian cancer. The primary target patient population for the study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents. Read More

#News

Ageing hands
#Age-related diseases (ARDs) #Ageing #Peptides #University of Birmingham

Natural peptide could protect against ‘inflammageing’

A naturally occurring peptide called ‘peptide inhibitor of trans-endothelial migration’ (PEPITEM) could potentially rejuvenate the immune response in older individuals, according to a new study. The authors believe the peptide could protect against ‘inflammageing’, widely believed to be the root cause of many age-related diseases. Read More

#News #Trending News

Peptide
#Environmental impact #Oncology #Peptides #Sustainability #The University of Manchester

Discovery offers greener and more efficient peptide production

Scientists from the University of Manchester have uncovered a more efficient and sustainable way to make peptide-based medicines, showing promising effectiveness in combating cancers. Peptides are used in many medicines, as well as in vaccines and nanomaterials. However, making peptides in the lab is currently a… Read More

#Cancer Research #News

Knee x-ray
#Bone disease #Peptides #Preclinical investigations #University of Birmingham

Peptide shows promise as therapeutic for bone loss disorders

Researchers have shown that a naturally occurring peptide holds promise as a new therapeutic for bone loss disorders and could have advantages over existing drugs. PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration) was first identified in 2015 by University of Birmingham researchers. The latest research… Read More

#News

Corporate collaboration
#Cancer #Orano Med #Orbit Discovery #Peptides #Radiopharmaceuticals

Collaboration to discover novel targeted radioligand therapies

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under… Read More

#Cancer Research #News

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

Peptide
#Collaboration #Contract Research Organisations (CROs) #IRBM #Merck #Partnership #Peptides

IRBM and Merck extend peptide therapeutics collaboration

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. “The success of this collaboration is reflected by the outstanding achievements in the delivery of orally available peptide candidates,” said… Read More

#Business & Investment #News